Drug Pipeline

Paclitaxel Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
399
Active Studies
184
Recruiting
120
Phase 3
10
Top Sponsors
102
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07198074
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin…
Trial sites expanded: 206 -> 211 locations
2026-06-12 NCT07061977
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation…
Trial sites expanded: 253 -> 260 locations
2026-06-12 NCT04090398
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy…
date change Primary completion pushed: 2026-06-30 -> 2027-06-30
2026-06-12 NCT04090398
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy…
date change Completion pushed: 2026-06-30 -> 2027-06-30
2026-06-12 NCT03907475
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid…
date change Primary completion pushed: 2026-06-01 -> 2027-06-01
2026-06-12 NCT03907475
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid…
date change Completion pushed: 2026-06-01 -> 2027-06-01
2026-06-11 NCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or…
date change Primary completion pushed: 2026-04 -> 2026-09-30
2026-06-11 NCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or…
date change Completion pushed: 2026-04 -> 2026-09-30
2026-06-11 NCT07044336
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial…
Enrollment increased: 700 -> 800 participants
2026-06-11 NCT07044336
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial…
Trial sites expanded: 314 -> 317 locations
2026-06-11 NCT07044336
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial…
date change Primary completion moved earlier: 2028-01-20 -> 2027-10-15
2026-06-10 NCT07221474
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in…
Trial sites expanded: 47 -> 51 locations
2026-06-09 NCT06619236
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in…
Enrollment increased: 448 -> 530 participants
2026-06-09 NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer…
Trial sites expanded: 42 -> 50 locations
2026-06-09 NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab…
Trial sites expanded: 115 -> 125 locations
2026-06-06 NCT05017012
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC)…
Trial completed
2026-06-06 NCT05017012
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC)…
Enrollment increased: 72 -> 142 participants
2026-06-06 NCT07007559
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in…
Trial sites expanded: 32 -> 44 locations
2026-06-06 NCT05285358
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine…
Recruitment suspended
2026-06-06 NCT05285358
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine…
critical why stopped: null → "Pending Interim analysis"
Showing 20 of 102 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-11 NCT07640932 Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small… Phase 2 Not Yet Recruiting
2026-06-08 NCT07634094 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and… Phase 2 Not Yet Recruiting
2026-06-04 NCT07628062 Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal… Phase 2 Not Yet Recruiting
2026-06-02 NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… Phase 3 Recruiting
2026-06-01 NCT07618910 Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC Phase 2 Not Yet Recruiting
2026-05-22 NCT07604766 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of… Phase 3 Not Yet Recruiting
2026-05-18 NCT07594548 Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or… Phase 1 Not Yet Recruiting
Active Studies by Phase
Phase 4
3
Phase 3
104
Phase 2/3
16
Phase 2
173
Phase 1/2
41
Phase 1
54
Early Phase 1
4
Not specified
4
Active Trials — top 25 of 399
NCT IDTitleConditionStatus
Phase 4
NCT03096418 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response Breast Neoplasm Female Recruiting
NCT05183126 Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With… Breast Cancer Recruiting
NCT05689671 Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… Non-Small Cell Lung Cancer Metastatic Active, Not Recruiting
Phase 3
NCT06644781 A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic… Esophageal Squamous Cell Carcinoma Recruiting
NCT07218809 AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low… Epithelial Ovarian Cancer Recruiting
NCT04342910 Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With… Gastric Cancer Recruiting
NCT07284134 JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced… Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting
NCT07377643 IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in… HER2-positive Breast Cancer Recruiting
NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally… Triple-Negative Breast Cancer (TNBC) Recruiting
NCT06072781 A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous… Low Grade Serous Ovarian Cancer Recruiting
NCT07168200 A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy… Advanced Cervical Cancer Recruiting
NCT06828354 A Study of SHR-A1811 in Subjects With Ovarian Cancer Ovarian Cancer Recruiting
NCT05357846 PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally… Squamous Cell Esophageal Carcinoma Recruiting
NCT06103864 A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's… Breast Cancer Recruiting
NCT04585490 Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and… Non Small Cell Lung Cancer Recruiting
NCT05624996 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for… Locally Advanced Lung Non-Small Cell Carcinoma Recruiting
NCT06958328 Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Recruiting
NCT06989112 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or… Endometrial Cancer Recruiting
NCT03801876 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Clinical Stage I Esophageal Adenocarcinoma AJCC v8 Recruiting
NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable… Triple Negative Breast Cancer Recruiting
NCT07071337 A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With… Metastatic Breast Cancer Recruiting
NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in… Carcinoma, Non-Small-Cell Lung Recruiting
NCT07002346 INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell… Ovarian Clear Cell Carcinoma Recruiting
NCT06340568 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy… Endometrial Cancer Recruiting
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab… Non Small Cell Lung Cancer Recruiting
Sponsors Running Paclitaxel Trials
Disease Areas
Get alerts when Paclitaxel trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free